

Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on April 2, 2026 | For discussion with your oncologist

TRIAL

Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study

NCT ID: NCT06073548 Phase: N/A Sponsor: Institut Curie Status: Not Yet Recruiting

SUMMARY

The goal of this prospective observational study is to learn about patient quality of life and experience and medical information needs during uveal melanoma post-treatment surveillance. Participants have previously undergone treatment for non-metastatic uveal melanoma and have integrated a oncological and / or ophthalmic surveillance protocol based on their individual genomic and / or clinical risk of recurrence. The main objectives it aims to assess are:

- * To evaluate the effect of satisfaction with communication with the oncologist/ophthalmologist during the oncology/ophthalmology surveillance visit 6 months after the start of surveillance (T1) on the overall level of health status/quality of life (QoL).
- * To explore the impact on psychosocial resources and needs such as fear of recurrence, anxiety and depression 6 months after the start of surveillance (T1) and 12 months after the start of surveillance (T2).
- * To document patients experience of care and communication during the first 12 months of surveillance.

Participants will fill in quality of life questionnaires at two timepoints. A sub-sample will be offered to participate in qualitative research interviews. Researchers will compare data from patients at low risk of recurrence with those at high risk of recurrence to see if there are significant differences with regards to quality of life, satisfaction with care and medical information needs.

KEY ELIGIBILITY CRITERIA

- * Patient aged 18 years or older.
- * Diagnosed with a non-metastatic uveal melanoma
- * Completion of primary tumour treatment e 6 months (+/- two months).
- * Able to respect scheduled visits.
- * Able to read and understand the language of the questionnaires.
- Two groups of patients will be identified:
 - 1. Patients with non-metastatic uveal melanoma at high risk for metastatic relapse defined as:
 - * T2b/c/d or e T3,
 - * or anomaly on either chromosome 3 or chromosome 8, found by CGH array or sequencing.
 - 2. Patients with non-metastatic uveal melanoma at low risk of recurrence defined as:

Total sites: 0 | 0 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT06073548) and public sources. Generated by FindMyCure.ai.